"I'EMPUS REQUISITION FORM NYS - 2024.11.04 Associated Study Study ID Phone: 800.739.4137 | Fax: 800.893.0276 | support@tempus.com If information is incomplete or missing, testing may be delayed. **A.PATIENT INFORMATION** ast Name MI First Name DOB (MM/DD/YYYY) Medical Record # Biological Sex Email Phone City Address (Street, Unit) State Postal Code Country **B.ORDERING PROVIDER INFORMATION** Ordering Provider (full legal name) NPI# Tempus Account # Facilitu Name Email (required for report deliveru) Fax Country Facility Address (Street, Unit) City State Postal Code Additional person to be copied Form completed by Name Email/Fax Name Email/Fax Facility Name Facility Name **C.TESTING OPTIONS** Test options Optional add-on tests (select all that apply): Test descriptions Specimen required xT (DNA): FFPE Tissue; Normal: Blood or Saliva Tissue Based Add-Ons: Solid Tumor/Normal 648-gene DNA sequencing test with normal match. PD-L1 IHC CLDN IHC FDA² Add xF liquid biopsy at time of order. $If I have not opted to add\ an xF test, I opt to convert my xT solid tumor order to an xF liquid biopsy test if necessary: the xF liquid biopsy test if nece$ MGMT Methylation² **MMRIHC** By converting immediately OR After an additional tissue request is attem HER2 IHC + FISH1,2 1p/19q FISH² FOLR1 IHC FDA² 1 See tempus.com/testing-resources for IHC and FISH tests ordered by cancer type, and Algorithmic Add-Ons logistics. 2 Powered by NeoGenomics FFPE Tissue, Blood (EDTA), or Bone xT (DNA): Solid Tumor OR Heme 648-gene DNA sequencing test. Marrow Aspirate (EDTA) xF (Liquid Biopsy): Blood (Streck) xF: 105-gene liquid biopsy test for solid tumors xG: 36-gene or xG+: 77-gene hereditary cancer xG (CancerNext®) (Hereditary): test, powered by Ambry Genetics. +RNAinsight® Add +RNAinsight® Blood (EDTA) or Saliva; Blood (PAXgene® tube required for RNA) xG+ (CancerNext-Expanded®) (Hereditary): Supplemental germline RNA sequencing, powered by Ambry Genetics. ${\tt D.SPECIMEN\ RETRIEVAL} \qquad \textit{See Tempus' specimen guidelines for collection instructions and further details}.$ FFPE Tissue / Bone Marrow Aspirate Submitting pathologist will choose FFPE Tissue if specimen details are not provided. Pathology Lab (Name, City) Specimen Collection Facility Patient status at time of specimen collection: Office/Non-Hospital Case Number Block # Date of Collection / Biopsy to be scheduled for Hospital Outpatient Not yet discharged OR Discharge date: Hospital Inpatient Blood / Saliva / Other Patient status at time of specimen collection: Mobile phlebotomy Send saliva kit to patient Sample previously submitted Office/Non-Hospital Hospital Outpatient Date of Collection: Specimen Collection Facility: Not yet discharged OR Discharge date: Hospital Inpatient **E.CURRENT DIAGNOSIS** Primary ICD-10 Codes (C & D codes only) Stage NSCL C Breast Pancreatic Other: Ш Other: ш

Colorectal Ovarian Prostate IV Disease Status (select all that apply): Has the patient had any type of transplant? Copy of patient's progress notes and/or medical records. Other: Metastatic No Copy of recent pathology report. Refractory Recurrent Copy of insurance card. Yes -Type: F.BILLING INFORMATION

Primary Insurance Plan Name

Policy #

Group#

Policy Holder Name

Policy Holder DOB

Patient Relationship to Policy Holder

Self Spouse Child Other:

Bill Type:
Insurance (must attach copy of card) Hospital/Institution
Medicare - Part B

Self pay/International

G.PROVIDER SIGNATURE AND CONSENT

My signature certifies that (1) the patient has received an explanation of the purpose, risks, and benefits of the ordered test(s); (2) the ordered test(s) are medically necessary and will inform the patient's treatment plan; (3) unless otherwise set forth on this form, the patient has recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer; and (4) the patient has provided informed consent that meets the requirements of applicable law for Tempus or its reference lab to: (a) collect and use the patient's samples (including genetic material) and health information and perform the ordered test(s); (b) obtain, receive, and release health information (including test results) as necessary for reimbursement or the processing of insurance claims; (c) retain and use samples and health information for an indefinite period of time in accordance with applicable law; and (d) deidentify such samples and information and use and share the resulting de-identified samples and information in accordance with applicable law.

Ordering Provider Signature

Printed Name (full legal name) Today's Date (MM/DD/YYYY)

In addition, my signature certifies that if xT and xF are ordered within 30 days of one another, the order is medically necessary because guidelines support the use of testing, turnaround time for tissue result may delay a treatment decision, the tissue is at risk to fail (e.g. small tissue, archived tissue) and I may not have a timely result to make a treatment decision; and/or genomic heterogeneity may cause available tissue to not be completely representative, and I want to make sure I have a complete mutation profile.

Please also complete the required New York State patient consent form. If this form is not completed it may result in order delays.

The following fields are for xG (CancerNext®) or xG+ (CancerNext-Expanded®) orders ONLY. Disregard if not testing for hereditary cancers. H.RELEVANT CLINICAL HISTORY (Previous cancer diagnosis, Gl polyps, etc.) J.FAMILY HISTORY None/No known family history Unknown Adopted Relationship to patient Maternal Paternal Age at diagnosis Details of relevant history J.ANCESTRY K.BONE MARROW TRANSPLANT White/Caucasian Middle Eastern Personal history of allogeneic bone marrow or peripheral stem cell transplant: No Native American Yes Hispanic East Asian Ashkenazi Jewish Note: Using a blood or saliva sample is not appropriate for patients who have undergone an allogeneic bone Black/African American South Asian marrow or peripheral stem cell transplant. L.PRIOR PERSONAL OR FAMILY HISTORY OF GENETIC TESTING No personal or family history of molecular and/or genetic testing. Relationship to patient: Family member: Microsatellite instability analysis: Germline testing

Stable (MSS)

Proteins present:

Unstable/High (MSI-High) Unstable/Low (MSI-Low)

Immunohistochemical staining

Proteins absent:

Test performed:

Test performed:

Somatic/tumor testing

Results:

Results: